NPPB and hydrops fetalis: We advocate for the inclusion of these biomarkers in existing CHF risk models alongside NT-proBNP, eGFR, and inflammatory markers, and for broadening the analytical scope to encompass a wider range of comorbidities and HF-related phenotypes to deepen our understanding of disease progression.